Introduction
Cardiovascular disease (CVD) is the main cause of death and morbidity worldwide, killing approximately 17.5 million people in 2012 (23, 37) . Both genetic and environmental factors contribute to CVD. The most common genetic contributions are considered to be polygenic, although the exact number and nature of genes involved has been difficult to determine as new genes are yet to be identified with the advancement of technology (16) . However, less common monogenic causes of CH have been well characterized in terms of the causative DNA variants and pathophysiology (10, 26) . Variation of the expression of genes involved in monogenic CH might provide clues to the causes of polygenic etiology of CH.
Hypertrophic cardiomyopathy (HCM) is the most common inherited form of CVD, affecting one in 500 adults and is the major cause of heart failure and sudden death in young people (21, 25, 26) . The condition is characterized by the asymmetric thickening of the cardiac wall, heart failure and risk of sudden death. A variety of mutations in genes coding sarcomere and cardiac filament proteins account for over 88% of familial HCM (5, 26, 31) . Mutations in two genes that encode myosin heavy chain 7 (MYH7) and cardiac myosin binding protein C (MYBPC3) are the most common causes of monogenic HCM (31, 39) . Familial dilated cardiomyopathies form another important group of monogenic CVD characterized by CH and heart failure, for which mutations in genes encoding sarcomeric proteins account for almost half of the known forms (15).
The study of genes involved in monogenic hypertrophy and failure have led to an understanding of disease mechanisms and might also provide explanations for more common polygenic forms of heart failure.
We have developed and characterized the hypertrophic heart rat (HHR), a unique polygenic normotensive model of spontaneous ventricular hypertrophy, cardiac failure and premature death (13) . Compared with their genetic control strain, the normal heart rat (NHR), HHR begin life with fewer cardiomyocytes that develop cellular hypertrophy leading to cardiac enlargement and heart failure (29).
Our aim was to study genes previously associated with human monogenic forms of dilated and hypertrophic cardiomyopathies in the polygenic etiology of cardiac hypertrophy in the HHR. We combined analyses of RNA expression and DNA sequence variation to identify those genes that might be of importance in the polygenic setting.
Materials and methods

Sample collection
The HHR and NHR strains have been described in detail elsewhere (13) . Two-dayold HHR and NHR (n=8 HHR, n=9 NHR) were euthanized by decapitation. At 4-, (n=10 HHR, n=10 NHR); 13-, (n=10 HHR, n=11 NHR); 33-(n=7 HHR, n=9 NHR) and 50-weeks of age (n=12 HHR, n=10 NHR) rats were euthanized using a lethal dose of pentobarbitone (Lethobarb). Hearts were removed and left ventricles (LV) were immediately dissected from atria. Cardiac weight indexes (CWI, mg/g) were calculated as the total heart weight (mg) relative to total body weight (g) of each animal (ref 28 and Figure 1 ).
The five age groups investigated represent different developmental stages in their life. Prior to hypertrophy (2-day-old), during the development of hypertrophy (4weeks), early hypertrophy (13-weeks), established hypertrophy (33-weeks), hypertrophy complicated by heart failure (50-weeks-old). This study was approved by the Animal Ethics Committees of the University of Melbourne and Deakin University, and ratified at Federation University Australia.
DNA and RNA extraction
DNA from LV was extracted using PureLink® Genomic Extraction kit (ThermoFisher Scientific). RNA from LV was extracted using miRNeasy kit (Qiagen). DNA was quantified by spectrophotometry using NanoDrop® 2000 and RNA was quantified by fluorescence using Qubit TM 3.0 Fluorometer and the RNA high sensitivity assay kit (ThermoFisher Scientific).
Genes investigated
For these focused studies we selected 42 genes ( Table 1 ) involved in monogenic forms of familial cardiomyopathies (5, 15, 31, 39) . Physiologically, most of these genes are involved in growth and contractility, regulation of mechanical-stress, calcium channels and a variety of muscle development pathways, mainly for cardiac filaments and sarcomere assembly (5, 31) .
DNA sequence variants in HHR were identified according to methods detailed previously (30) . Briefly, we sequenced the whole-genome of one male 13-week-old NHR and one age-matched HHR. Variants were analyzed according to GATK best practices (35) and functional annotation was performed using SnpEff software (4) .
Results were stored in a database developed "in-house" and then we identified unique single nucleotide polymorphisms (SNPs) and insertions/deletions (InDels) in the NHR and HHR (30) . mRNA expression of the genes listed in Table 1 microRNA (miRNA) arrays were conducted using the Agilent rat microRNA microarray kit 16.0 in left ventricles of 2 days old male HHR and age-matched NHR (n=4/group). The data obtained has been deposited in the National Center for Biotechnology Information Gene Expression Omnibus database with series accession number GSE38710. Differentially expressed miRNAs were identified using
Partek Genomics Suit v6.6 with FDR set as <0.05.
In silico investigations
We combined in silico approaches to explore a link between gene expression and DNA sequencing data from the HHR and NHR and human studies available online.
We investigated the possibility that miRNAs might be involved in regulating mRNA expression pre-and post-transcriptionally using three algorithms individually (miRWalk 2.0, (7, 8) miRanda (3) and TargetScan (11)) as a comparative platform to predict possible miRNA binding sites within the sequence in and around each gene of interest. We also used miRWalk 2.0 to investigate experimentally validated miRNA-mRNA interactions and evaluate which miRNAs targeted the genes under investigation.
As DNA methylation can modulate gene expression by compacting DNA sequences, we investigated if any of the DNA sites were differentially methylated in CVD using the Disease Meth database 2.0 (38) .
Gene expression in human hearts
We also investigated the mRNA expression of the genes listed identified in HHR in human cardiac samples from the dataset "heart failure arising from different etiologies" in the repository Gene Expression Omnibus (GEO) reference series GSE1145 (2, 9) (n=11 control hearts and n=15 idiopathic dilated hearts). We then determined the expression of the genes investigated using the GEO tool GEO2R.
Results
DNA Sequence Analyses
DNA sequencing in and around the 42 genes of interest revealed greater number of unique DNA variants discovered in the HHR (compared to the rat reference genome) with 851 SNPs and 491 InDels, as opposed to 383 SNPs and 316 InDels in the NHR (Table 1) . We found no evidence of DNA sequence variation in 6 genes in the NHR (namely Csrp3, Emd, Gla, Mylk2, Pln and Taz) and 3 genes in the HHR (Emd, Myoz2 and Tpm1, Table 1 ).
In both the HHR and NHR, most unique variants were located in intergenic or intronic regions. However, we found 11 unique synonymous SNPs in exonic regions in the HHR and 2 in the NHR. These SNPs were located in genes encoding actinin alpha 2 (Actn2), desmin (Des), ryanodine receptor 2 (Ryr2), troponin T type 2 (Tnnt2) and vinculin (Vcl) in the HHR; and Ryr2 and Vcl in the NHR. Interestingly, only one unique non-synonymous missense variant (gGt>gTt) in an exonic region was found in the Vcl gene in the NHR changing the aminoacid from glycine to valine.
Cardiac RNA Expression Analyses
The relative fold changes (FC) in mRNA expression in the HHR relative to NHR were never greater than 4-fold for any of the 42 genes under investigation. We found that 29 of the 42 genes showed significant differential expression for at least one age Genes differentially expressed were not consistent throughout the age groups, possibly reflecting developmental stage-specific regulation. At 2 days old, only four genes were differentially expressed (Figure 2a ). In contrast, at 4 weeks of age, we observed 50% of genes differentially expressed, the highest prevalence of all the age groups (Figure 2b ). Most of the differences at this age presented increased expression. For some genes (such as Gla, Jup, Lamp2 and Pln) differential expression was evident only at 4 weeks of age. The differential expression of other genes (such as Actc1, Cav3 and Fhl2) became first evident at 4 weeks of age and then persisted throughout adulthood. Differences in the expression of other genes (such as Tnnt2, Myoz2 and Myl3) appeared at 4 weeks of age, but disappeared in later adulthood. Still other genes (such as Ankrd1) did not show differential expression until later adulthood (Figure 2, 3 and 4).
Two genes, those encoding desmoglein 2 (Dsg2) and transthyretin (Ttr) were significantly differentially expressed at all ages in the HHR compared with NHR.
Dsg2 was underexpressed in the hearts of HHR at all ages sampled, whereas Ttr was significantly downregulated at day 2 in the neonatal period but significantly upregulated at all subsequent ages corresponding to the development of cardiomyocyte hypertrophy ( Figure 2 ). Ttr also showed greater expression in adult human idiopathic cardiomyopathy ( Figure 4 ).
The analysis of human idiopathic cardiomyopathy revealed that 16 orthologous genes differentially expressed of the 42 genes investigated. We found only 9 of those 16 genes were also differentially expressed in at least one rat age.
Predicted miRNA binding sites
We also predicted possible miRNA binding sites within and around each gene region. Potentially, there are over 220,000 miRNA binding sites in the gene coding regions alone and almost 54,000 in the promoter regions (Table 2 ). However, our comparison of validated miRNA-mRNA interactions to miRNAs differentially expressed in HHR compared to NHR in our microarray data found two miRNAs (miR-34a-5p and miR-17-5p) upregulated in the HHR (Table 3) . Interestingly, those two miRNAs interact with five of the genes investigated, plakophilin 2 (Pkp2), RNA binding motif protein 20 (Rbm20), ryanodine receptor 2 (Ryr2), tropomyosin 1 (Tpm1) and vinculin (Vcl) (14, 19, 24) . Although not statistically significant, the gene expression of Pkp2, Ryr2, Tpm1 and Vcl is downregulated in 2 days old HHR (FC=0.93, 0.95, 0.89 and 0.88, respectively).
Other analyses
Scans of published GWAS (using GWASdb v2 (22) ) data also indicated the presence of SNPs found in the 42 genes investigated that are associated with CVD traits in humans (Table 4) .
Surprisingly no methylation profiles have been reported in human heart
related diseases for any of the genes in our dataset.
Discussion
The HHR and their NHR genetic control are derived from the spontaneously hypertensive rat (SHR) and Fisher 344 rat and provide a unique model of left ventricular hypertrophy independent of high blood pressure and heart failure.
Although HHR and NHR have a polygenic background, it is not unreasonable to presume that genes best known for their major mutations causing human cardiac and failure might also encompass DNA variants with a more subtle quantitative impact on cardiac structure and function. Here we sought to determine whether any of the 42 genes implicated in Mendelian human hypertrophic and dilated cardiomyopathies might also be relevant to the polygenic hypertrophy of HHReither as DNA sequence variants or abnormal gene expression patterns. We had the advantage with our life course approach to also examine the ontogeny of the expressions of these genes and their relationships with the developmental stages of hypertrophy in the HHR.
Molecular genetic studies have identified over 1400 mutations responsible for inherited cardiomyopathies and genetic testing is offered to identify genetic causes in families or assess family members at risk (26, 34) . However, emerging data suggests that compound mutations have an additive role causing a gene dosage effect influencing the severity and progression of HCM (17, 20, 27) . Such interactions at the level of monogenic cardiomyopathic disease provide general support for the hypothesis that interaction between other DNA variants in the same genes might influence polygenic cardiac hypertrophy.
Among the sequence variants identified in our sequencing analyses we found 11 synonymous SNPs in exonic regions in the HHR and one nonsynonymous SNP in the NHR. It is well established that nonsynonymous mutations may impact aminoacid sequences and therefore human health (18) . However, synonymous variants which had previously been regarded as "silent" mutations and thought to have no effect on disease phenotype, have been reported to also cause changes in protein-protein interactions. Importantly, studies suggest that these synonymous mutations contribute to human disease risk and other complex traits (32). The synonymous variants we discovered (Table 1) Interestingly, HHR are born with smaller and fewer cardiomyocytes than NHR.
We believe that this reduced endowment is important for the subsequent development of cardiomyocyte hypertrophy, which becomes evident in early adolescence (4 weeks, Figure 1 ), when increased pressure and volume loads in the growing animals place proportionately greater stress on the fewer individual myocytes (29). By 13 weeks of age, both cardiac and cardiomyocyte hypertrophy are established (ref 13 and Figure 1 ), but in the end this is counterproductive, as the enlarged cells do not function efficiently and gradually deteriorate, leading to heart failure (evident as early as 30 weeks of age) and premature death (towards 50 weeks of age) (13, 29) . These pathophysiological phenotypic changes can provide context for the developmental stage-specific changes in gene expression we observed.
Our analysis of gene expression showed that at 2 days old, when HHR hearts are smaller than NHR (29), the genes encoding cardiac filaments and sarcomeric proteins are generally underexpressed (Figure 2 ). Whether this is a cause or effect of the fewer, smaller cells is not possible to say from these data. As the cells begin to hypertrophy and throughout the rest of their lives, most of these genes are overexpressed. These findings demonstrate that the left ventricle undergoes changes in gene expression that could be related to the pathophysiology of the hypertrophy (36) . Interestingly, the switch of the Ttr gene from underexpressed in neonates to overexpressed in adults suggest stage-specific regulation. Ttr encodes a protein for exosome production and high protein levels in serum have been previously associated with lung cancer (6) and heart failure caused by accumulation of transthyretin amyloid fibrils in the heart (33). Additionally, the genes for cardiac alpha actin 1 (Actc1), caveolin-3 (Cav3) and four and a half LIM domains 2 (Fhl2) are upregulated in adult HHR and have been associated with cardiomyopathies in mice and humans (1, 28) . Conversely, the persistent underexpression of Dsg2 suggests a constitutive difference between HHR and NHR that appears independent of the pathophysiological changes with age. Interestingly, the majority of genes identified in HHR were not differentially expressed in the human samples ( Figure 2 ). This might reflect the nature of the diseases in the human repository that is composed primarily of samples from human idiopathic dilated cardiomyopathy rather than Mendelian human hypertrophic cardiomyopathy. Furthermore, as we were unable to establish the age of the human samples, we cannot make direct comparisons to our rat data to further our understanding of gene expression patterns with the progression of HCM.
In order to provide a comprehensive perspective about the processes involved in this pathology, we investigated DNA methylation profiles and SNPs published in GWAS data of the genes investigated. We were unable to find any relevant methylation data supporting further analyses as the majority of the studies available was performed in a variety of cancers and only few and individual studies are available in CVD. However, two SNPs found in the GWAS data located in the cardiac troponin T2 (TNNT2) gene are associated with cardiac troponin-T levels and directly correlated to heart failure. (40) These challenges in merging DNA, RNA and epigenome data highlight the importance of comprehensive studies publicly available.
Our findings provide evidence of the involvement of monogenic genes in polygenic hypertrophic but might only account for part of the genes responsible for this disease. The prevalence of rare variants and unidentified genes responsible for
HCM are yet to be elucidated. Furthermore, the interaction mechanisms used by these genes deserve more attention and might aid professionals in determining diagnostics and prognosis of the disease. 
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